Wednesday, June 18, 2008

New Safety Information regarding Liver Injury and Hypersensitivity associated with TYSABRI (natalizumab)

From Health Canada:
Biogen Idec Canada Inc., in consultation with Health Canada, would like to inform you about new safety information regarding the risk of liver injury and hypersensitivity in patients receiving TYSABRI (natalizumab).
Tysabri For Health Professionals
For the Public

No comments: